As depicted in Figure 4, there was a general elevation from baseline to the moment the tumor exhibited its first complete response (CR) or partial response (PR) in all cytokines, with the exceptions being IL-6 and IL-17A in Cohort 1. The gene discussed is IL17A; the disease is neoplasm.